Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May 15;128(10):1958-1966.
doi: 10.1002/cncr.34131. Epub 2022 Feb 24.

Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2)

Emanuela Palmerini  1 , Cristina Meazza  2 , Angela Tamburini  3 , Gianni Bisogno  4 , Virginia Ferraresi  5 , Sebastian D Asaftei  6 , Giuseppe M Milano  7 , Luca Coccoli  8 , Carla Manzitti  9 , Roberto Luksch  2 , Massimo Serra  1 , Marco Gambarotti  10 , Davide M Donati  11   12 , Katia Scotlandi  13 , Rossella Bertulli  2 , Claudio Favre  3 , Alessandra Longhi  1 , Massimo E Abate  14 , Silverio Perrotta  15 , Maurizio Mascarin  16 , Paolo D'Angelo  17 , Marilena Cesari  1 , Eric L Staals  11   12 , Emanuela Marchesi  18 , Elisa Carretta  1 , Toni Ibrahim  1 , Paolo G Casali  2 , Piero Picci  18 , Franca Fagioli  6   19 , Stefano Ferrari  1
Affiliations
Clinical Trial

Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2)

Emanuela Palmerini et al. Cancer. .

Abstract

Background: According to retrospective osteosarcoma series, ABCB1/P-glycoprotein (Pgp) overexpression predicts for poor outcomes. A prospective trial to assess a risk-adapted treatment strategy using mifamurtide in Pgp+ patients was performed.

Methods: This was a phase 2, multicenter, uncontrolled trial including patients 40 years old or younger with nonmetastatic extremity high-grade osteosarcoma stratified according to Pgp expression. All patients received high-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively. In Pgp+ patients, mifamurtide was added postoperatively and combined with MAP for a good histologic response (necrosis ≥ 90%; good responders [GRs]) or with high-dose ifosfamide (HDIFO) at 3 g/m2 /d on days 1 to 5 for a histologic response < 90% (poor responders [PRs]). Pgp- patients received MAP postoperatively. After an amendment, the cumulative dose of methotrexate was increased from 60 to 120 g/m2 (from 5 to 10 courses). The primary end point was event-free survival (EFS). A postamendment analysis was performed.

Results: In all, 279 patients were recruited, and 194 were included in the postamendment analysis: 70 (36%) were Pgp-, and 124 (64%) were Pgp+. The median follow-up was 51 months. For Pgp+ patients, 5-year EFS after definitive surgery (null hypothesis, 40%) was 69.8% (90% confidence interval [CI], 62.2%-76.2%): 59.8% in PRs and 83.7% in GRs. For Pgp- patients, the 5-year EFS rate was 66.4% (90% CI, 55.6%-75.1%).

Conclusions: This study showed that adjuvant mifamurtide, combined with HDIFO for a poor response to induction chemotherapy, could improve EFS in Pgp+ patients. Overall, the outcomes compared favorably with previous series. Mifamurtide and HDIFO as salvage chemotherapy are worth further study.

Trial registration: ClinicalTrials.gov NCT01459484.

Keywords: ATP binding cassette subfamily B member 1 (ABCB1); P-glycoprotein; adolescents and young adults (AYAs); chemotherapy; high-grade bone sarcoma; mifamurtide; osteosarcoma; pediatric bone tumors.

PubMed Disclaimer

Conflict of interest statement

Emanuela Palmerini has served on advisory boards for Amgen, Daiichi Sankyo, Lilly, Deciphera, Eusa Pharma, and SynOx Therapeutics; has received other research support from Bristol‐Myers Squibb, Pfizer, PharmaMar, Daiichi Sankyo, and Incyte; and has received travel support from Lilly, PharmaMar, and Takeda. Virginia Ferraresi has served on advisory boards for Bristol‐Myers Squibb, Novartis, MSD, Pierre‐Fabre, and PharmaMar. Giuseppe M. Milano has served on advisory boards for GSK and Pfizer. Marco Gambarotti has received institutional funding from Amgen outside the submitted work. Paolo D’Angelo reports being a member of the Associazione Italiana di Ematologia e Oncologia Pediatrica and the International Society of Paediatric Oncology. Eric L. Staals has served on advisory boards for Daiichi Sankyo. Toni Ibrahim reports participation on a board for Amgen‐PharmaMar. Piero Picci has received institutional funding from Amgen and PharmaMar outside the submitted work. Stefano Ferrari has received honoraria from Takeda and PharmaMar. The other authors made no disclosures.

Figures

Figure 1
Figure 1
Chemotherapy and mifamurtide schedule and doses by Pgp expression. Pgp indicates P‐glycoprotein.
Figure 2
Figure 2
Study profile. GR indicates good responder; Pgp, P‐glycoprotein; PR, poor responder.
Figure 3
Figure 3
(A) EFS among Pgp+ patients. (B) OS among Pgp+ patients. (C) EFS among Pgp+ patients according to necrosis. (D) OS among Pgp+ patients according to necrosis. (E) EFS among Pgp– patients. (F) OS among Pgp– patients. EFS indicates event‐free survival; GR, good responder; OS, overall survival; Pgp, P‐glycoprotein; PR, poor responder.
See this image and copyright information in PMC

References

    1. Gitelis S. Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment. 2nd ed. J Bone Joint Surg Am. 2001;83:801‐802.
    1. Tilsley O. Soft tissue and bone tumours in adults. In: Hanna L, Crosby T, Macbeth F, eds. Practical Clinical Oncology. Cambridge University Press; 2008:335‐346.
    1. Baumhoer D, Böhling, TO , & Cates, JMM , et al. Osteosarcoma. In: WHO Classification of Tumours ‐ Soft Tissue and Bone Tumours. 5th ed. IARC Press; 2020:403‐409.
    1. Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO‐EURACAN‐GENTURIS‐ERN PaedCan clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32, 1520‐1536. 10.1016/j.annonc.2021.08.1995 - DOI - PubMed
    1. Bielack SS, Kempf‐Bielack B, Delling G, et al. Prognostic factors in high‐grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776‐790. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources